전임상 이미징 시장 : 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of preclinical imaging Market

The global preclinical imaging market was valued at USD 3.42 billion in 2025 and is projected to grow from USD 3.72 billion in 2026 to USD 6.85 billion by 2034, registering a CAGR of 8.0% during the forecast period. North America dominated the market in 2025, accounting for 40.64% of global revenue, supported by strong pharmaceutical R&D investments, advanced healthcare infrastructure, and increasing adoption of innovative imaging technologies.

Preclinical imaging is a non-invasive imaging technique used extensively in drug discovery, disease research, and translational medicine. The technology enables researchers to monitor disease progression, evaluate therapeutic responses, and study biological processes in real time using animal models. Increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and neurological diseases is accelerating demand for advanced imaging solutions across pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and academic institutions.

Market Size and Forecast

• 2025 Market Size: USD 3.42 Billion
• 2026 Market Size: USD 3.72 Billion
• 2034 Market Size: USD 6.85 Billion
• CAGR (2026-2034): 8.0%

The market continues to benefit from expanding drug discovery pipelines, increasing biomedical research activities, and rising investments in preclinical studies worldwide.

Market Trends

Expansion of Advanced Optical Imaging Technologies

Advanced optical imaging technologies such as fluorescence imaging and bioluminescence imaging are becoming increasingly important in preclinical research. These technologies provide real-time visualization, high sensitivity, and non-invasive monitoring capabilities, making them ideal for longitudinal studies.

The growing adoption of optical imaging has encouraged strategic acquisitions and collaborations among major industry participants. In February 2024, Bruker expanded its preclinical imaging portfolio through the acquisition of Spectral Instruments Imaging LLC, strengthening its capabilities in in-vivo optical imaging solutions.

Market Drivers

Rising Investments in Drug Discovery and Biomedical Research

The growing number of preclinical research programs worldwide is a major factor driving market expansion. Pharmaceutical and biotechnology companies are increasing investments in early-stage drug development to identify novel therapies and improve clinical success rates.

In January 2025, the U.S. National Institutes of Health (NIH) invested approximately USD 48 billion in medical research initiatives. Such investments significantly increase demand for imaging platforms including PET, SPECT, micro-CT, micro-MRI, ultrasound imaging, and optical imaging systems.

Growing demand for non-invasive imaging technologies and expansion of global drug discovery activities continue to support market growth.

Market Restraints

High Equipment and Software Costs

Despite technological advancements, the high cost of sophisticated imaging systems remains a significant barrier, particularly in emerging economies. Advanced imaging instruments require substantial capital investment, along with ongoing maintenance, calibration, and software upgrade expenses.

These financial constraints limit adoption among smaller research institutions and healthcare facilities, thereby restricting market penetration in developing regions.

Market Opportunities

Technological Advancements and AI Integration

The integration of artificial intelligence, multimodal imaging platforms, advanced image reconstruction, and automated analysis tools is creating new opportunities across the market.

AI-powered imaging solutions improve data interpretation, accelerate research workflows, and enhance translational outcomes. Companies are increasingly investing in next-generation imaging technologies that offer higher sensitivity, automation, and analytical capabilities.

Market Challenges

Limited Infrastructure in Developing Regions

Many emerging countries continue to face challenges related to inadequate healthcare infrastructure, limited research funding, and shortages of skilled professionals. These factors restrict the widespread adoption of advanced preclinical imaging systems and slow market expansion in low-resource settings.

Segmentation Analysis

By Type

The market is segmented into hardware and software.

The hardware segment dominated the market in 2025 due to rising deployment of advanced imaging instruments across research facilities. Increasing product launches by leading manufacturers continue to strengthen this segment.

The software segment is expected to register the fastest growth with a CAGR of 8.5% during the forecast period, supported by increasing adoption of AI-based imaging analysis platforms.

By Application

The market is segmented into:

• Oncology
• Cardiology
• Neurology
• Infectious Diseases
• Others

The oncology segment held the largest share of 38.3% in 2025, driven by the growing global cancer burden and increasing investments in oncology research.

The cardiology segment is projected to grow at a CAGR of 7.3% through 2034.

By End User

The market includes:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Others

The pharmaceutical and biotechnology companies segment dominated the market in 2025 and is expected to account for 42.4% market share in 2026, driven by increasing R&D expenditure and growing adoption of imaging technologies during drug development.

The CRO segment is anticipated to grow at a CAGR of 8.8% during the forecast period.

Regional Outlook

North America

North America remained the largest regional market, valued at USD 1.39 billion in 2025. Strong pharmaceutical innovation, increasing clinical research activities, and advanced healthcare infrastructure continue to support regional dominance.

United States

The U.S. market is expected to reach USD 1.35 billion in 2026, accounting for approximately 36.4% of global revenue.

Europe

Europe is projected to reach USD 0.99 billion in 2026, growing at a CAGR of 7.1%. Strong academic research networks and government-supported healthcare innovation programs are supporting regional expansion.

Asia Pacific

Asia Pacific is expected to reach USD 0.89 billion in 2026, driven by rapid growth in pharmaceutical research, healthcare infrastructure development, and increasing clinical studies.

China is projected to generate USD 0.29 billion in 2026, while India is expected to reach USD 0.10 billion.

Latin America and Middle East & Africa

Both regions are anticipated to witness steady growth due to increasing healthcare investments, expanding research activities, and improving access to advanced medical technologies.

Competitive Landscape

The market is highly competitive, with major companies focusing on product innovation, acquisitions, collaborations, and new technology launches.

Key companies operating in the market include:

• FUJIFILM Corporation
• Bruker
• Revvity
• Mediso Ltd.
• Siemens Healthineers
• Miltenyi Biotec
• MR Solutions

Recent product launches, imaging software advancements, and AI-enabled analysis platforms are strengthening competitive positioning across the industry.

Key Industry Developments

• December 2025: Mediso installed its nanoScan 7T PET/MRI preclinical imaging system in the U.S.
• September 2025: Revvity launched Living Image Synergy AI multimodal analysis software.
• September 2025: Revvity opened a new In Vivo Imaging Center of Excellence in North Carolina.
• June 2025: FUJIFILM launched the Vevo F2 LAZR-X20 Photoacoustic Imaging Platform.
• April 2025: Revvity introduced the VivoJect Image-Guided Injection System.
• September 2023: Revvity launched the Quantum GX3 microCT imaging platform.

Conclusion

The global preclinical imaging market is positioned for strong growth, increasing from USD 3.42 billion in 2025 to USD 6.85 billion by 2034. Growth is being driven by expanding pharmaceutical R&D activities, rising chronic disease prevalence, increasing adoption of non-invasive imaging technologies, and continuous technological innovation. Advances in AI-powered imaging analysis, multimodal imaging systems, and optical imaging technologies are expected to further strengthen market adoption. With growing investments from pharmaceutical companies, biotechnology firms, research institutes, and CROs, the preclinical imaging market is expected to remain a critical component of future drug discovery and translational research efforts.

Segmentation By Type, Application, End User, and Region

By Type * Hardware

• Instruments
• Optical Imaging
• Nuclear Imaging
• Micro-MRI Systems
• Micro-CT Systems
• Ultrasound Imaging
• Others
  • Consumables
• Software

By Application * Oncology

• Cardiology
• Neurology
• Infectious Diseases
• Others

By End User * Pharmaceutical and Biotechnology Companies

• Academic & Research Institutes
• Contract Research Organization (CRO)
• Others

By Region * North America (By Type, By Application, By End User, and by Country)

• U.S. (By Application)
• Canada (By Application)
• Europe (By Type, By Application, By End User, and by Country/Sub-region)
  • U.K. (By Application)
  • Germany (By Application)
  • France (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Scandinavia (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Type, By Application, By End User, and by Country/Sub-region)
  • China (By Application)
  • Japan (By Application)
  • India (By Application)
  • Australia (By Application)
  • Southeast Asia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Type, By Application, By End User, and by Country/Sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Type, By Application, By End User, and by Country/Sub-region)
  • GCC (By Application)
  • South Africa (By Application)
  • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Number of Clinical Trials, Key Countries/Region, 2025
• 4.2. Technological Advancements in Preclinical Imaging Devices
• 4.3. New Product Launches, Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions & Partnerships

5. Global Preclinical Imaging Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Hardware
    • 5.1.1.1. Instruments
      • 5.1.1.1.1. Optical Imaging
      • 5.1.1.1.2. Nuclear Imaging
      • 5.1.1.1.3. Micro-MRI Systems
      • 5.1.1.1.4. Micro-CT Systems
      • 5.1.1.1.5. Ultrasound Imaging
      • 5.1.1.1.6. Others
    • 5.1.1.2. Consumables
  • 5.1.2. Software
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Oncology
  • 5.2.2. Cardiology
  • 5.2.3. Neurology
  • 5.2.4. Infectious Diseases
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Pharmaceutical and Biotechnology Companies
  • 5.3.2. Academic & Research Institutes
  • 5.3.3. Contract Research Organization (CRO)
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Preclinical Imaging Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Hardware
    • 6.1.1.1. Instruments
      • 6.1.1.1.1. Optical Imaging
      • 6.1.1.1.2. Nuclear Imaging
      • 6.1.1.1.3. Micro-MRI Systems
      • 6.1.1.1.4. Micro-CT Systems
      • 6.1.1.1.5. Ultrasound Imaging
      • 6.1.1.1.6. Others
    • 6.1.1.2. Consumables
  • 6.1.2. Software
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Oncology
  • 6.2.2. Cardiology
  • 6.2.3. Neurology
  • 6.2.4. Infectious Diseases
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Pharmaceutical and Biotechnology Companies
  • 6.3.2. Academic & Research Institutes
  • 6.3.3. Contract Research Organization (CRO)
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Preclinical Imaging Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Hardware
    • 7.1.1.1. Instruments
      • 7.1.1.1.1. Optical Imaging
      • 7.1.1.1.2. Nuclear Imaging
      • 7.1.1.1.3. Micro-MRI Systems
      • 7.1.1.1.4. Micro-CT Systems
      • 7.1.1.1.5. Ultrasound Imaging
      • 7.1.1.1.6. Others
    • 7.1.1.2. Consumables
  • 7.1.2. Software
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Oncology
  • 7.2.2. Cardiology
  • 7.2.3. Neurology
  • 7.2.4. Infectious Diseases
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Pharmaceutical and Biotechnology Companies
  • 7.3.2. Academic & Research Institutes
  • 7.3.3. Contract Research Organization (CRO)
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Application
  • 7.4.2. Germany
    • 7.4.2.1. By Application
  • 7.4.3. France
    • 7.4.3.1. By Application
  • 7.4.4. Spain
    • 7.4.4.1. By Application
  • 7.4.5. Italy
    • 7.4.5.1. By Application
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Application
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Application

8. Asia Pacific Preclinical Imaging Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Hardware
    • 8.1.1.1. Instruments
      • 8.1.1.1.1. Optical Imaging
      • 8.1.1.1.2. Nuclear Imaging
      • 8.1.1.1.3. Micro-MRI Systems
      • 8.1.1.1.4. Micro-CT Systems
      • 8.1.1.1.5. Ultrasound Imaging
      • 8.1.1.1.6. Others
    • 8.1.1.2. Consumables
  • 8.1.2. Software
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Oncology
  • 8.2.2. Cardiology
  • 8.2.3. Neurology
  • 8.2.4. Infectious Diseases
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Pharmaceutical and Biotechnology Companies
  • 8.3.2. Academic & Research Institutes
  • 8.3.3. Contract Research Organization (CRO)
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Application
  • 8.4.2. Australia
    • 8.4.2.1. By Application
  • 8.4.3. China
    • 8.4.3.1. By Application
  • 8.4.4. India
    • 8.4.4.1. By Application
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Application
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Application

9. Latin America Preclinical Imaging Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Hardware
    • 9.1.1.1. Instruments
      • 9.1.1.1.1. Optical Imaging
      • 9.1.1.1.2. Nuclear Imaging
      • 9.1.1.1.3. Micro-MRI Systems
      • 9.1.1.1.4. Micro-CT Systems
      • 9.1.1.1.5. Ultrasound Imaging
      • 9.1.1.1.6. Others
    • 9.1.1.2. Consumables
  • 9.1.2. Software
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Oncology
  • 9.2.2. Cardiology
  • 9.2.3. Neurology
  • 9.2.4. Infectious Diseases
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Pharmaceutical and Biotechnology Companies
  • 9.3.2. Academic & Research Institutes
  • 9.3.3. Contract Research Organization (CRO)
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Preclinical Imaging Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Hardware
    • 10.1.1.1. Instruments
      • 10.1.1.1.1. Optical Imaging
      • 10.1.1.1.2. Nuclear Imaging
      • 10.1.1.1.3. Micro-MRI Systems
      • 10.1.1.1.4. Micro-CT Systems
      • 10.1.1.1.5. Ultrasound Imaging
      • 10.1.1.1.6. Others
    • 10.1.1.2. Consumables
  • 10.1.2. Software
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Oncology
  • 10.2.2. Cardiology
  • 10.2.3. Neurology
  • 10.2.4. Infectious Diseases
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Pharmaceutical and Biotechnology Companies
  • 10.3.2. Academic & Research Institutes
  • 10.3.3. Contract Research Organization (CRO)
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Application
  • 10.4.2. South Africa
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. FUJIFILM Corporation
  • 11.2.2. Bruker
  • 11.2.3. Revvity
  • 11.2.4. Mediso Ltd.
  • 11.2.5. Siemens Healthineers
  • 11.2.6. Miltenyi Biotec
  • 11.2.7. MILabs B.V.
  • 11.2.8. MR Solutions
  • 11.2.9. Trifoil Imaging LLC
  • 11.2.10. Aspect Imaging Ltd.